SUPRATECHNIC (S) Pte Ltd, a leading regional distributor of marine, instrumentation and healthcare solutions, has secured sole nationwide distribution rights in Singapore for IQAir.
Founded in Switzerland in 1963, IQAir is an air quality technology brand trusted in hospitals and critical healthcare environments worldwide.
This appointment formalises and elevates existing partnership of the SGX Mainboard-listed USP Group Ltd subsidiary with the Swiss manufacturer to the sole authorised distributor for Singapore.
This milestone expands Supratechnic’s healthcare division and secures its role as a key provider of clinical-grade infrastructure.
“Our objective was never merely to sell more units. Over the years, we have invested steadily in building the service infrastructure required to uphold IQAir’s exacting standards – from technical training and after-sales support to market-wide service coverage,” commented Supratechnic’s CEO Melvin Tan.
“This sole nationwide distributorship appointment is not the beginning of that journey but a recognition of the work already done. Our responsibility now is to honour that trust by delivering consistently, at the highest standard, every day.”
Access to genuine IQAir products
Alongside this appointment, Supratechnic officially launched Suprayi, a digital platform curated for clinically proven health solutions.
The name Suprayi brings together “supra” which represents excellence and standards above the ordinary and “yi” (医), the Chinese character for healing and medicine.
Together, the name embodies the platform’s mission to provide trusted, effective and elevated health solutions that support healthier living.
Operated directly by Supratechnic, Suprayi is the official e-commerce and advisory channel for IQAir products in Singapore.
The platform provides customers with access to genuine IQAir products, local warranty coverage, expert technical advice and dependable after-sales support from the authorised distributor.
IQAir is known globally for its proprietary HyperHEPA filtration technology which captures ultrafine particles down to 0.003 microns by filtering up to 100 times more particles than conventional air purifiers, including viruses, bacteria, tobacco smoke and combustion particles.
Independent laboratories verify its performance while hospitals and specialist clinics rely on its strict international safety certifications.
Notably, the Hong Kong Hospital Authority selected IQAir as its air purifier of choice for combating SARS (Severe Acute Respiratory Syndrome) following rigorous government testing – and turned to IQAir again when COVID-19 emerged.
This real-world deployment across two of the most critical public health crises is a testament to IQAir’s unmatched clinical credibility.
The timing of this sole nationwide distributorship appointment reflects a market in transition.
Singapore’s persistent air quality challenges – from seasonal transboundary haze to urban emissions and VOCs (volatile organic compounds) from renovation materials and rising pet ownership in compact homes – have fundamentally changed how households, workplaces and healthcare facilities think about indoor air.
This shift is evident in the local air purifier market which was valued at approximately US$199 mil in 2024 and is forecast to reach US$280 mil by 2030. – April 14, 2026
